Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

13.62
-0.1100-0.80%
Pre-market: 13.50-0.1197-0.88%05:39 EDT
Volume:5.43M
Turnover:73.87M
Market Cap:10.87B
PE:-12.19
High:13.73
Open:13.51
Low:13.44
Close:13.73
52wk High:29.23
52wk Low:12.07
Shares:797.75M
Float Shares:152.34M
Volume Ratio:0.87
T/O Rate:3.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1177
EPS(LYR):-1.4439
ROE:-192.50%
ROA:-101.61%
PB:17.25
PE(LYR):-9.43

Loading ...

The Bull Case For Summit Therapeutics (SMMT) Could Change Following Ridinilazole Sale And Royalty Deal

Simply Wall St.
·
Jul 15

Summit Therapeutics Divests Ridinilazole Asset to AI Biopharma Biossil

MT Newswires Live
·
Jul 14

Summit Therapeutics Signs Agreement to Sell Phase Iii Asset Ridinilazole to Biossil, Inc.

THOMSON REUTERS
·
Jul 14

Summit Therapeutics - to Receive $500,000 Upfront and up to $104.5 Mln in Milestones Plus Tiered Royalties

THOMSON REUTERS
·
Jul 14

Has Summit Therapeutics (SMMT) Become Undervalued As It Pulls Its $500 Million Offering?

Simply Wall St.
·
Jun 25

UK Vehicle Production Rebounds in May, Halting Four-Month Decline

Deep News
·
Jun 25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Damora Therapeutics (DMRA), Summit Therapeutics (SMMT) and Elicio Therapeutics (ELTX)

TIPRANKS
·
Jun 22

Summit Therapeutics shareholders approve 8 million-share increase to 2020 stock incentive plan

Reuters
·
Jun 13

Summit Therapeutics Co-CEO Mahkam Zanganeh reports purchase of 3,810,000 shares for $49.99 million

Reuters
·
Jun 13

Summit Therapeutics co-CEO Robert W. Duggan acquires 3,810,000 shares for $49.99 million

Reuters
·
Jun 13

Summit Therapeutics Withdraws Public Offering Due to Market Conditions

MT Newswires Live
·
Jun 11

Summit Therapeutics withdraws proposed underwritten public offering

TIPRANKS
·
Jun 11

BUZZ-Summit Therapeutics rebounds after pulling stock offering

Reuters
·
Jun 11

BRIEF-Summit Therapeutics Withdraws Proposed Underwritten Public Offering Effective- SEC Filing

Reuters
·
Jun 11

Summit Therapeutics - No Securities to Be Sold in Proposed Underwritten Public Offering - SEC Filing

THOMSON REUTERS
·
Jun 11

Summit Therapeutics Stock Slides to 52-Week Low on Plans for Secondary Offering

Dow Jones
·
Jun 11

Summit Therapeutics falls -10.2%

TIPRANKS
·
Jun 11

Summit Therapeutics put volume heavy and directionally bearish

TIPRANKS
·
Jun 10

BRIEF-Summit Therapeutics Announces Proposed Public Offering Of Common Stock

Reuters
·
Jun 10

Summit Therapeutics launches USD 500 million common stock offering

Reuters
·
Jun 10